Results 121 to 130 of about 113,104 (262)

Ultrasound priming gated by solid tumor hallmarks to guide CAR-T therapy. [PDF]

open access: yesSci Adv
Guo T   +20 more
europepmc   +1 more source

Truncated CD19 as a selection marker for the isolation of stem cell-derived β-cells

open access: yesDisease Models & Mechanisms
Luo Ting Huang   +8 more
doaj   +1 more source

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

open access: yesBarrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu   +9 more
wiley   +1 more source

Novel Noninvasive Broad‐Spectrum Infrared Treatment of Ulcerative Colitis by Modulating T‐Cell Relocation

open access: yesENERGY &ENVIRONMENTAL MATERIALS, EarlyView.
A novel graphene‐based broad‐spectrum infrared (BSIR) device is developed for the noninvasive treatment of ulcerative colitis (UC). BSIR irradiation effectively alleviates colonic inflammation and accelerates mucosal recovery by inducing the systemic relocation of T lymphocytes to the spleen.
Siyu Chen   +15 more
wiley   +1 more source

The multiple hit model of infantile and epileptic spasms: The 2025 update

open access: yesEpilepsia Open, EarlyView.
Abstract Objective Infantile and epileptic spasms syndrome (IESS) is a developmental and epileptic encephalopathy manifesting with epileptic spasms and poor neurodevelopmental outcomes. There is an urgent need for the development of more effective and tolerated therapies.
Aristea S. Galanopoulou   +6 more
wiley   +1 more source

B7 homolog 3-targeted CAR-T cells secreting EGFR T-cell engagers for improved control of glioblastoma progression. [PDF]

open access: yesMol Biomed
Zhang Z   +9 more
europepmc   +1 more source

Generation of Allogeneic CAR‐T Circumvents Functional Deficits in Patient‐Derived Autologous Product for Glioblastoma

open access: yesInternational Journal of Cancer, EarlyView.
Clinical trials of chimeric antigen receptor T‐cell (CAR‐T) therapies in glioblastoma have shown limited clinical benefits. Whether this may be explained by the basal quality of CAR‐T products, which are currently generated using patient, autologous T‐cells, has been little explored.
Sabra K. Salim   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy